Urteste publishes first peer-reviewed paper on Panuri cancer test

Urteste said its first peer-reviewed paper on Panuri, a urine-based pancreatic cancer test, has been published in Diagnostics as the company advances European clinical testing. The publication marks a milestone for the Warsaw-listed biotech as it seeks regulatory clearance and prepares to present updates at ADLM 2026.

Why it matters: - The publication gives Panuri peer-reviewed scientific validation as Urteste pushes the test toward potential European market approval. - Panuri is designed to support earlier detection of pancreatic ductal adenocarcinoma, a cancer that is often found late and remains difficult to diagnose. - The company is also using the publication to support business development ahead of a major diagnostics conference next week.

What happened: - Urteste said it published the first peer-reviewed scientific article on Panuri, its investigational urine-based pancreatic cancer test. - The paper, titled "Development and Analytical Evaluation of Urine-Based Test for Detection of Pancreatic Cancer," appeared in Diagnostics. - Urteste said the publication documents analytical validation completed during assay development. - The article is available in Diagnostics (2026): Read the paper. - Urteste said management will attend the Association for Diagnostics & Laboratory Medicine 2026 Annual Scientific Meeting & Clinical Lab Expo in Anaheim, California, from July 26–30, 2026.

The details: - Panuri is an investigational in vitro diagnostic device and has not yet received CE marking. - The test is undergoing a multicenter clinical performance study across Europe under the In Vitro Diagnostic Medical Devices Regulation. - Urteste said the study is being run at 30 clinical sites in Poland, Italy and Hungary. - The study is expected to include about 550 evaluable participants. - Panuri is being developed to support diagnosis of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. - The test measures disease-associated proteolytic activity in urine using proprietary synthetic peptides. - Urteste said the analytical development of the assay showed 89% analytical sensitivity, with a 95% confidence interval of 78.5% to 94.9%. - Urteste said the assay showed 75% analytical specificity, with a 95% confidence interval of 64.8% to 83.5%. - Urteste said the assay demonstrated high analytical precision, including repeatability, within-laboratory precision and inter-laboratory reproducibility, with coefficients of variation below 10%. - Urteste currently has 13 prototypes of diagnostic tests covering breast, brain, stomach, bile ducts, ovaries, bladder, endometrium, kidneys, colon, lungs, liver, pancreas and prostate cancers. - Urteste said those cancers account for nearly 70% of all cancer-related deaths worldwide. - Urteste's technology detects cancers by measuring enzyme activity in urine and looking for changes in urine color intensity. - Urteste specializes in early cancer detection and says its technology is designed to identify biochemical changes associated with selected cancers.

Between the lines: - The peer-reviewed paper can help Urteste build credibility with regulators, potential partners and investors while the clinical study is still underway. - The ADLM appearance suggests the company is trying to turn scientific progress into commercial and strategic interest. - The company's broader pipeline shows Urteste is pursuing a platform approach, not a single-test business.

What's next: - Urteste said the ongoing European study will support the regulatory process for Panuri under IVDR. - The company plans to present progress on Panuri, the publication and the clinical study at ADLM 2026. - Urteste expects to meet potential strategic and commercial partners during the conference. - The next key readout is likely clinical performance data that can support future regulatory and commercialization steps.

The bottom line: - Urteste has moved Panuri from lab validation into peer-reviewed science and multicenter clinical testing, two steps that matter most for eventual regulatory and commercial progress.